Calliditas Therapeutics' 2020 Annual Report Published
Calliditas Therapeutics AB (Nasdaq: CALT) announces the availability of its 2020 Annual Report on its website.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) announces the availability of its 2020 Annual Report on its website. This report provides insights into the company's financial performance and strategic direction, particularly focusing on its lead product, Nefecon, aimed at treating IgA nephropathy. Calliditas is conducting a global Phase 3 study for Nefecon with the intent to commercialize it in the U.S. The announcement complies with the Securities Markets Act, highlighting the company's commitment to transparency.
Positive
- Nefecon is a novel oral formulation targeting IgA nephropathy, addressing a significant unmet medical need.
- Active global Phase 3 study indicates progression towards potential commercialization.
Negative
- No specific financial metrics or results disclosed in the report may lead to uncertainty among investors.
Details
News Market Reaction – CALT
The recorded move for CALT in the trading session of this news was -0.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's website: www.calliditas.com.
This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14:30 CET on April 27, 2021.
For further information, please contact:
Marie Galay, IR Manager, Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
About Calliditas
Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Calliditas AR 2020_EN_ | |
https://mb.cision.com/Public/16574/3334502/83e78aaa2310d2ec.pdf | Annual report 2020 published EN |
View original content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-2020-annual-report-published-301277937.html
SOURCE Calliditas Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.